Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the trea⦠read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
$0.36
Price-1.98%
-$0.01
$24.634m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-
5y CAGR-$27.112m
-
1y CAGR-
3y CAGR-
5y CAGR-$0.64
-
1y CAGR-
3y CAGR-
5y CAGR-$459.150k
$11.635m
Assets$12.094m
Liabilities$113.250k
Debt1.0%
-
Debt to EBITDA-$26.549m
-
1y CAGR-
3y CAGR-
5y CAGR